苯磺酸左旋氨氯地平联合拉贝洛尔治疗中重度妊娠期高血压伴蛋白尿患者的临床研究OA
Clinical trial of levamlodipine besylate combined with labetalol in patients with moderate to severe gestational hypertension with proteinuria
目的 研究苯磺酸左旋氨氯地平片联合拉贝洛尔片治疗中重度妊娠期高血压伴蛋白尿患者的临床疗效和安全性.方法 将中重度妊娠期高血压伴蛋白尿患者根据治疗方案分为对照组和试验组.对照组口服拉贝洛尔片,每次100 mg,每天3次,试验组在对照组的基础上口服苯磺酸左旋氨氯地平片,每次2.5 mg,每天1次,2组均用药至分娩前1 d.比较2组患者的临床疗效、血压指标、肾功能指标、不良妊娠结局,并进行安全性评价.结果 共入组80例,对照组入组38例、试验组入组42例.治疗后,试验组治疗总有效率90.48％(38例/42例)显著高于对照组的71.05％(27例/38例),在统计学上差异有统计学意义(P＜0.05).治疗后,试验组、对照组收缩压(SBP)水平分别为(127.26±6.68)和(131.71±7.51)mmHg,舒张压(DBP)水平分别为(82.71±6.95)和(86.50±6.48)mmHg,血清肌酐(Scr)水平分别为(57.78±10.69)和(64.24±11.57)μmol·L-1,尿酸(UA)水平分别为(256.19±37.77)和(274.76±40.39)μmol·L-1,尿素氮(BUN)水平分别为(3.79±0.73)和(4.19±0.76)mmol·L-1,24 h 蛋白尿(24 h UP)水平分别为(1.77±0.36)和(2.01±0.42)g,不良妊娠结局总发生率分别为9.52％(4例/42例)和26.32％(10例/38例),上述指标在2组间比较,在统计学上差异均有统计学意义(P＜0.05,P＜0.01).试验组和对照组总药物不良反应发生率分别为16.67％(7例/42例)和10.53％(4例/38例),在统计学上差异无统计学意义(P＞0.05).结论 苯磺酸左旋氨氯地平片联合拉贝洛尔片治疗中重度妊娠期高血压伴蛋白尿患者能够取得较好的临床效果,可有效降低血压,改善肾功能、动脉血管弹性、内皮功能,减轻炎症反应,改善不良妊娠结局,且安全性较好.
Objective To study the clinical effect and safety of levamlodipine besylate tablets combined with labetalol tablets in patients with moderate to severe gestational hypertension with proteinuria.Methods Patients with moderate to severe gestational hypertension and proteinuria were divided into control group and treatment group based on treatment plans.The control group was given oral labetalol tablets,100 mg each time,3 times a day;the treatment group was given oral levamlodipine besylate tablets on the basis of the control group,2.5 mg each time,once a day.Both groups were treated until 1 day before delivery.The clinical efficacy,blood pressure indexes,renal function indexes,adverse pregnancy outcomes;safety of the two groups were compared.Results A total of 80 patients were enrolled;the control group included 38 cases and the treatment group included 42 cases.The total clinical effective rate of the treatment group was 90.48％(38 cases/42 cases),which was significantly higher than 71.05％(27 cases/38 cases)of the control group,with statistically significant difference(P＜0.05).After treatment,the systolic blood pressure(SBP)levels in the treatment group and the control group were(127.26±6.68)and(131.71±7.51)mmHg,respectively;the diastolic blood pressure(DBP)levels were(82.71±6.95)and(86.50±6.48)mmHg,respectively;serum creatinine(Scr)levels were(57.78±10.69)and(64.24±11.57)μmol·L-1,respectively;uric acid(UA)levels were(256.19±37.77)and(274.76±40.39)μmol·L-1,respectively;blood urea nitrogen(BUN)levels were(3.79±0.73)and(4.19±0.76)mmol·L-1,respectively;24-hour urine protein(24 h UP)levels were(1.77±0.36)and(2.01±0.42)g,respectively;the total incidence of adverse pregnancy outcomes was 9.52％(4 cases/42 cases)and 26.32％(10 cases/38 cases),respectively,with statistically significant differences of the above indicators between two groups(P＜0.05,P＜0.01).The total incidence of adverse drug reactions in the treatment group and the control group were 16.67％(7 cases/42 cases)and 10.53％(4 cases/38 cases)(P＞0.05).Conclusion Levamlodipine besylate tablets combined with labetalol tablets can achieve good clinical results in the treatment of patients with moderate to severe gestational hypertension with proteinuria,effectively reduce blood pressure,improve renal function,improve arterial vascular elasticity and vascular endothelial function,reduce inflammatory response;improve adverse pregnancy outcomes,with good safety.
孙应妹;范懿隽;张红丽
安徽医科大学第二附属医院妇产科,安徽 合肥 230000安徽医科大学第二附属医院妇产科,安徽 合肥 230000安徽医科大学第二附属医院妇产科,安徽 合肥 230000
医药卫生
苯磺酸左旋氨氯地平片拉贝洛尔片妊娠期高血压蛋白尿
levamlodipine besylate tabletlabetalol tabletgestational hypertensionproteinuria
《中国临床药理学杂志》 2026 (12)
1659-1664,6
评论